9 Meters Biopharma Accounts Payable

The latest accounts payable for NMTR is $4.2M as of March 2023. That compares with $1.9M in the prior-year period — up 121.3% year over year. Investors often review this figure alongside 9 Meters Biopharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, NMTR's accounts payable moved from $1.9M to $4.2M — a 121.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in 9 Meters Biopharma's operating scale or balance-sheet position.

A accounts payable figure of $4.2M for NMTR is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting NMTR's accounts payable ($4.2M), review year-over-year change from $1.9M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack 9 Meters Biopharma's accounts payable against similar Technology names. You can also browse sector and industry screens on Stockcircle for a broader set of Technology companies and their key multiples and fundamentals.